Covishield and Covaxin Immunogenicity | 16 Mar 2024
A recent study led by scientists from the National Centre for Biological Sciences (NCBS) and conducted across 11 institutes has provided compelling insights into the immunogenicity of 2 primary Covid-19 vaccines in India: Covishield and Covaxin.
- Immunogenicity refers to the ability of a substance, such as a vaccine or antigen, to provoke an immune response in the body.
- This response typically involves the production of antibodies and activation of immune cells, leading to protection against infection or disease.
- The recent study examined the immune responses induced by Covishield and Covaxin vaccines against SARS-CoV-2.
- Covishield, utilising a virus vector to deliver the coronavirus spike protein, consistently elicited a more robust immune response (higher antibody levels in both seronegative (individuals without prior exposure) and seropositive (individuals with prior exposure)) compared to Covaxin, an inactivated virus vaccine.
- Additionally, Covishield elicited a greater number of T cells, indicating a stronger immune response.
Read more: Covishield and Covaxin